Search
Search Results
-
Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease
BackgroundAlzheimer disease (AD) is a major health problem of aging, with tremendous burden on healthcare systems, patients, and families globally....
-
Therapeutic preference for Alzheimer’s disease treatments: a discrete choice experiment with caregivers and neurologists
BackgroundAlzheimer’s disease (AD) is a major global health crisis in need of more effective therapies. However, difficult choices to optimize...
-
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease
Two monoclonal antibodies (mAbs), aducanumab and lecanemab, have received accelerated approval from the US FDA for initiation of treatment in early...
-
Anti-Amyloid Immunotherapies for Alzheimer’s Disease: A 2023 Clinical Update
The amyloid cascade hypothesis is a useful framework for therapeutic development in Alzheimer’s disease (AD). Amyloid b 1-42 (Aβ) has been the main...
-
The search for clarity regarding “clinically meaningful outcomes” in Alzheimer disease clinical trials: CLARITY-AD and Beyond
CLARITY-AD is an 18-month, double-blinded, placebo-controlled, phase 3 trial which examined the safety and efficacy of the anti-amyloid agent,...
-
VascuConNet: an enhanced connectivity network for vascular segmentation
Medical image segmentation commonly involves diverse tissue types and structures, including tasks such as blood vessel segmentation and nerve fiber...
-
-
Commentaries: Lecanemab: pioneering the way as the first approved drug for Alzheimer’s disease treatment
Alzheimer's disease (AD) is a progressive neurodegenerative disorder marked by cognitive decline and neuronal abnormalities. Current therapies...
-
Amyloid-β (Aβ) immunotherapy induced microhemorrhages are associated with activated perivascular macrophages and peripheral monocyte recruitment in Alzheimer’s disease mice
BackgroundAmyloid-related imaging abnormalities (ARIA) have been identified as the most common and serious adverse events resulting from pathological...
-
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
BackgroundThis review describes the research and development process of gantenerumab, a fully human anti-amyloid monoclonal antibody in development...
-
Avoiding future controversies in the Alzheimer’s disease space through understanding the aducanumab data and FDA review
Key points of disagreement between the aducanumab FDA statistical review, which had primarily negative conclusions, and the clinical review, which...
-
Roles of peripheral lipoproteins and cholesteryl ester transfer protein in the vascular contributions to cognitive impairment and dementia
This narrative review focuses on the role of cholesteryl ester transfer protein (CETP) and peripheral lipoproteins in the vascular contributions to...
-
Emerging diagnostics and therapeutics for Alzheimer disease
Alzheimer disease (AD) is the most common contributor to dementia in the world, but strategies that slow or prevent its clinical progression have...
-
Apolipoprotein E in Alzheimer’s disease trajectories and the next-generation clinical care pathway
Alzheimer’s disease (AD) is a complex, progressive primary neurodegenerative disease. Since pivotal genetic studies in 1993, the ε4 allele of the...
-
Border-associated macrophages promote cerebral amyloid angiopathy and cognitive impairment through vascular oxidative stress
BackgroundCerebral amyloid angiopathy (CAA) is a devastating condition common in patients with Alzheimer’s disease but also observed in the general...
-
Perspectives and challenges in patient stratification in Alzheimer’s disease
BackgroundPatient stratification is the division of a patient population into distinct subgroups based on the presence or absence of particular...
-
Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease
Immunotherapy against amyloid-beta (Aβ) is a promising option for the treatment of Alzheimer’s disease (AD). Aβ exists as various species, including...
-
DCNN-based prediction model for detection of age-related macular degeneration from color fundus images
AbstractAge-related macular degeneration (AMD) is a degenerative disorder in the macular region of the eye. AMD is the leading cause of irreversible...
